Thank you again for submitting your manuscript on SPP-Derlin-TRC8 in XBP1u proteolysis for our consideration. It has now been reviewed by three expert referees, whose comments are copied below. As you will see, at least two of the reviewers consider these findings of interest and potential importance. However, all referees remain to varying degrees unconvinced that your present data provide sufficiently compelling evidence for the proposed key role of SPP-Derlin-TRC8 in XBP1u degradation, nor for the functional significance of this process. In our view, these well-taken concerns at present preclude publication in The EMBO Journal; but in light of the principle interest of this work, we would nevertheless be inclined to give you an opportunity to improve and clarify these aspects by way of a revised version of this manuscript.
strong. The model would predict that many other ectodomains should also slow down SPP cleavage of XBP1u. This needs to be tested, either with a chimeric ectodomain or potentially even with the the ectodomain of the protein described in the Voss et al publication (cited by the authors). While that protein does not require shedding when being cleaved by SPPL3, this protein's ectodomain may well block cleavage by SPP if fused to the XBPu1 transmembrane domain. 6. The physiological relevance of the XBP1u cleavage remains enigmatic. The authors make a prediction based on their model (page 16 end of first paragraph , ER-stressed cells) which can easily be tested.
Referee #2: SUMMARY In this manuscript, the authors explore a putative role for the intramembrane protease signal peptide peptidase (SPP) in ER-associated degradation (ERAD). In doing so, they identify and characterize and interactions of SPP with Derlin1, an established ERAD component and putative rhomboid-like protease, and Trc8, an ER-resident ubiquitin ligase implicated in previously in US2-induced degradation of MHC Class I. They describe a regulatory protein of the Unfolded Protein Response (UPR), XBP1u (unspliced) as a substrate of SPP. They demonstrate that XBP1u adopts a type II orientation by virtue of a transmembrane domain that has so far been uncharacterized. Moreover, the authors suggest that Derlin1 acts in the context of a receptor for XBP1u in order for SPP to access it. XBP1u does not seem to lose its ectodomain due to an interaction with Derlin1. The authors also provide evidence that the XBP1u form attenuates XBP1s action (and hence UPR activation) by targeting it for degradation. Collectively, the authors propose an SPP regulated mechanism of UPR tuning through degradation of XBP1s via XBP1u.
The findings presented by Chen et al. reveal several novel aspects regarding the relationship between ERAD and UPR regulation. They demonstrate the presence of Derlin1 in a 500kD complex with SPP and Trc8 that also binds XBP1u. They convincingly show that XBP1u can adopt the conformation of a type II membrane protein, for which the hydrophobic sequence responsible is cleaved by SPP. A role for Derlin1-mediated recognition of the XBP1u ectodomain is also clearly demonstrated. Overall the manuscript was well written and the data clearly presented. The authors have cited appropriate references have provided a sufficient number of supplemental figures to complement the primary data. Although of very good quality overall, there are several issues with both text and the data that should be addressed. These are briefly mentioned below. QUESTIONS Question 1. In the Lee (2010) study cited, an interaction between SPP and Derlin1 was not observed. Can the authors offer an explanation as to this difference with Figure 1A ? Detergent solubisation conditions perhaps? If so, what might this say about the stability/assembly of such a complex? Question 2. Of note is that XBP1u only seems to be partially in a membrane-integrated state ( Figure  2C , 2D). The authors postulate that inefficient glycosylation is the reason why only a fraction of XBP1u-N-FLAG has its glycan acceptor site modified ( Figure 2D ) but Figure 2E (bottom) depicts what appears to be very little loss of XBP1-C-GFP signal from the cell in question. This raises the question, what is the relative fraction of type II to membrane-associated XBP1u? Figure E2C indicates that 75% is protected but that does not seem to agree with Figure 2D (R223N). Can the authors please explain and/or speculate on the potential for multiple XBP1u orientations.
Question 3. Along similar lines, can the XBP1u subcellular localization/orientation be recapitulated with endogenous forms? What is the relative expression level of FLAG-XBP1u to endogenous? Could the elevated, exogneous expression be causing XBP1u to adopt an Type II conformation? Question 4. In Figure 2F , can ubiquitinated XBP1u be detected or all Ub chains removed during sample processing? In general, some demonstration of Ub conjugation would be useful to support an active role for Trc8 in this complex.
Question 5. For the mutants tested in Figure 3 , was their orientation with respect to ER membrane determined (as in Figure 2 ) and did they adopt a type II orientation with the same frequency as the wild type? Question 6. The 25kD fragment detected in Figure 2F is very weak and would not appear to correlate with the levels observed in Figure 4B . Can the authors comment on the relative levels of this fragment appear so different? Question 7. In Figure 5B , no difference in the amount XBP1u co-IP with SPP WT or DA is observed. If XBP1u is unable to be processed by SPP-DA, I would have expected that more might be observed. Can the authors shed some light on why no change was observed? Question 8. In Figure 7A and 7B, several prominent bands listed as "unidentifiable coimmunoprecipitated proteins" are listed. There is a striking difference between XBP1u and XBP1uΔ with respect to these bands. For instance, the higher band observed in SPP-D286A is missing as is the lowest band of DerlinG189V. It would appear that these bands represent interesting interactors or modified XBP1u forms. Could the authors address what they might represent or perhaps determine at least whether they represent XBP1u (modified) or a completely different protein.
Question 9. Is the stabilizing effect of the ectodomain specific for the sequence or merely for the presence of additional sequence following the TM domain? Specifically, would the ectodomain be sufficient for Derlin1 interaction if a chimera is made with a different type II protein?
Question 10. Does the Derlin1-G180V mutant still assemble with SPP-Trc8 in the 500kD complex?
Question 11. Is Derlin1 still present along with SPP-Trc8 in complexes when XBP1uΔ is expressed? Specifically, the temporal aspects of these interactions are not entirely clear. Is Derlin1 is brought to the complex by XBP1u ectodomain or is it poised within the 500kD complex, waiting for XBP1u for come along?
MINOR COMMENTS Comment 1. The resolution of images in Figure E2G makes interpretation a bit difficult. Comment 2. Pg. 14, first sentence. Fig 2D should Contrary to the current consensus in the field that XBP1u is a peripheral membrane protein in the ER (located entirely on the cytosolic side), the authors claim that XBP1u is synthesized as a type II transmembrane protein in the ER and degraded by a 500-kDa ERAD complex consisting of SPP, Derlin-1 and TRC8. However, if intramembrane cleavage of XBP1u by SPP triggers subsequent proteosomal degradation, the authors must observe both full length XBP1u and cleaved form of XBP1u in pulse chase experiments. This reviewer cannot believe the authors' story until the authors provide convincing data for the two-step cleavage of XBP1u (first by SPP and second by proteasome) by pulse chase experiments. N-terminal fragment of XBP1u observed was too faint in cycloheximde chase experiment (Fig. 2F) to support the authors' claim.
If the authors insist that "Despite that, upon inhibiting the proteasome we observed mainly accumulation of the full-length XBP1u and only traces of the SPP-generated cleavage fragment ( Fig  2D and 4C ). Since epoxomicin is specific for the proteasome and does not inhibit SPP (Bland et al, 2003) , the stabilization effect on the full-length form indicates that under our experimental conditions there is a so far unrecognized functional coupling between SPP and the proteasome, which is known to associate with the ER-membrane (Palmer et al., 1996) " (p.13, line 2 from the bottom -p.14, line 6), the authors should uncover the coupling mechanism for this manuscript to be published in EMBO J. This is a critical point.
Identification of the 500-kDa SPP-Derlin1-TRC8 complex was interesting to this reviewer, however, the XBP1u part probably represents an artifact resulting from overexpression of XBP1u, because there are a lot of discrepancy in the data. Discrepancy 1) a) Immunofluorescence; XBP1u-N-GFP is localized only in the ER in Fig. 2B . However, bright fluorescence from XBP1u-N-GFP and XBP1u-C-GFP was seen in the nucleus (Fig. 2E and Fig.  E2A and E2B). 1) b) Fig. 2F ; XBP1u exists as full-length (ER) form in epoxomicin-treated cells, whereas bright fluorescence was observed in the nucleus of epoxomicin-treated cells expressing XBP1u-GFP in Fig. 4B . 1) c) Only half of XBP1u remained associated with ER membrane after sodium carbonate wash in Fig. 2C . Only small fraction of FLAG-XBP1u was glycosylated (Fig. 2D) . Despite these facts, degradation of XBP1u was blocked almost completely by co-expression with SPP mutant D265A in Fig. 5A , which seems too effective than expected to this reviewer. The authors must show how much of XBP1u stays in the ER as a type II transmembrane protein quantitatively.
2) Fig. 6 ; why did cleavage-deficient XBP1u mutant mt2 reduce expression of UPR reporter? If the authors' claim is correct, XBP1u mutant mt2 remains associated with the ER, and therefore is unable to down regulate XBP1s. The data in Fig. E4 contradict the authors' claim.
Specific points 1) Fig. 2G ; show the band of XBP1s in western and show the bands of cDNA corresponding to XBP1s and XBP1u mRNA by RT-PCR to say that epoxomicin treatment reduced XBP1u levels probably by IRE1-mediated reduction of the XBP1 pre-mRNA, which upon accumulation of unfolded proteins activates the canonical UPR signaling. 2) Fig. 3A; show the localization and topology of the two mutants and examine whether the two mutants are cleaved or not cleaved by SPP as in Fig. 4C . We are pleased that two referees were positive about our paper, and thank all three referees for their helpful comments. We now provide several new experiments addressing the previous shortcomings of our manuscript and further supporting our claims:
-We now apply an additional approach to confirm topology of XBP1u as a type II membrane protein. Importantly, this new strategy allowed us to demonstrate that XBP1u persists in this membrane-spanning form when trapped by the catalytic SPP D265A mutant. Over all, in the revised manuscript, we provide evidence by four independent methods that the predominant fraction of XBP1u is an ER membrane protein with a type II topology.
-We show that the g-secretase-specific inhibitor DAPT, even at very high dose, does not interfere with XBP1u turnover, providing strong evidence that residual degradation in presence of SPP inhibitors is not caused by g-secretase-catalyzed cleavage.
-We detect the C-terminal fragment generated by SPP-catalyzed XBP1u cleavage and show that, like the N-terminal fragment, also this luminal portion is efficiently degraded by the ERAD machinery.
-By western analysis of immunoisolated XBP1u we show that it is ubiquitinated; moreover, we provide evidence that this step is mediated by the E3 ligase TRC8.
-Domain swap and pulse-chase experiments provide further evidence that, in addition to determinants in the XBP1u transmembrane domain, also the C-terminal portion contributes to recognition by the SPP-Derlin1-TRC8 complex. Intriguingly, this tail was sufficient to drive degradation of a stable type II membrane protein. This highlights the role of Derlin1 in recruiting XBP1u to SPP for subsequent proteolytic degradation.
Moreover, we provided additional controls as requested, and sharpen our claims concerning the influence of XBP1u in UPR tuning. In the course of the revision, we have changed the order of the figures now showing first the data on the UPR tuning (Fig 5. Inhibition of UPR by XBP1u is independent of SPP-catalyzed cleavage) before focusing on the molecular mechanism of how the SPP ERAD complex functionally interacts with XBP1u (Fig 6. XBP1u is specifically recognized by SPP-Derlin1-TRC8 complex). Last, we have changed our title, which now better summarizes our main scientific claims. Over all, we are convinced that we now can satisfy all critical issues that have been raised and this indeed strengthens our conclusions dramatically. Below we provide a point-by-point response to the referees' comments (answers in italics).
Referee #1:
This reviewer asked us to address the following points:
1. Epoxomicin stabilizes XBP1u in Fig. 1F 2. The authors demonstrate that SPP overexpression enhances cleavage. But this only shows that SPP CAN cleave XBP1u, but -like for many other proteases -this does not yet prove the cleavage under physiological conditions. Moreover, although both pharmacological inhibitors have previously been shown to block SPP, such drugs are rarely specific. In fact, L685 has initially been identified as a potent inhibitor of gamma-secretase. Interestingly, L685 induces a much stronger accumulation of XBP1u than the more specific SPP inhibitor ZLL ketone. Similar to point 1 this may indicate a role of gamma-secretase in an alternatively oriented XBP1u. To resolve this issue the authors need to knock-down SPP and presenilin (or use the corresponding knock-out cells) and demonstrate the selective role of SPP and not of presenilin/gamma-secretase. XBP1u (Christianson et al., 2011) ."
4. The proteolytic processing of XBP1u is only partially characterized in the manuscript. While suitable antibodies may not be available detecting the N-and C-terminal fragments, the authors should simply generate a double-tagged XBP1u protein and show the N-and C-terminal cleavage fragments in the presence or absence of the endogenous SPP.
We have addressed this point and now show the fate of the C-terminal fragment (Fig E4D). Interestingly this fragment is efficiently degraded by the proteasome in the manner of a soluble ERAD substrate.
5. In the current version of the manuscript it is tempting to speculate that Derlin1-XBP1u interaction obviates the need for a prior shedding event. However, evidence for this mechanism is not yet very strong. The model would predict that many other ectodomains should also slow down SPP cleavage of XBP1u. This needs to be tested, either with a chimeric ectodomain or potentially even with the the ectodomain of the protein described in the Voss et al publication (cited by the authors). While that protein does not require shedding when being cleaved by SPPL3, this protein's ectodomain may well block cleavage by SPP if fused to the XBPu1 transmembrane domain. (Fig 7B and E8C) and that, vice versa, the tail fused to a substrate of the endosomal SPPL2a protease targets it to SPP (Fig 8B) , we now provide compelling evidence for our claims.
We followed on this interesting idea and performed domain swap experiments with the type II membrane protein invariant chain (Fig 8A-C and E8A-B). Interestingly, this new data shows that the C-terminal tail of XBP1u alone is sufficient to target a type II membrane protein to the SPPdependent ERAD pathway. By showing that removal of the tail obviates the need for Derlin1 in XBP1u degradation
6. The physiological relevance of the XBP1u cleavage remains enigmatic. The authors make a prediction based on their model (page 16 end of first paragraph, ER-stressed cells) which can easily be tested. (Fig 5A and E5) and interferes with the endogenous UPR signaling machinery (Fig 5B) . Since previous reports already demonstrated a physiological role of XBP1u in regulating UPR transcription factors (Yoshida, 2006; Tirosh, 2006; Yoshida, 2009) 
Since inhibition of SPP is expected to cause accumulation of other substrates and likely off-target effects are observed, we have chosen to block XBP1u turnover by specifc point mutations in the XBP1u transmembrane domain. This revealed that the membrane-anchored form triggers degradation of ectopically expressed XBP1s

Referee #2:
This reviewer asked us to address the following points: Question 1. In the Lee (2010) study cited, an interaction between SPP and Derlin1 was not observed. Can the authors offer an explanation as to this difference with Figure 1A ? Detergent solubisation conditions perhaps? If so, what might this say about the stability/assembly of such a complex?
The analysis by Lee et al. (2010) Question 2. Of note is that XBP1u only seems to be partially in a membrane-integrated state ( Figure  2C, 2D) . The authors postulate that inefficient glycosylation is the reason why only a fraction of XBP1u-N-FLAG has its glycan acceptor site modified ( Figure 2D ) but Figure 2E (bottom) depicts what appears to be very little loss of XBP1-C-GFP signal from the cell in question. This raises the question, what is the relative fraction of type II to membrane-associated XBP1u? Figure E2C indicates that 75% is protected but that does not seem to agree with Figure 2D (R223N) . Can the authors please explain and/or speculate on the potential for multiple XBP1u orientations.
In order to further support our claim that the predominant pool of XBP1u is a type II membrane protein, we studied by immunofluorescence analysis accessibilityof the C-terminal HA-tagged
XBP1u upon selective permeabilization of the plasma membrane ( Fig E2D) . As stated on page 9 we assume that the apparent discrepancy in the glycosylation efficiency in Fig 2D and (Rainer, Chem. Rev. 1998) .
Over all, we now provide evidence for this membrane-spanning topology by using four independent assays, namely 1.) analysis of a glycosylation mutant (Fig 2D) , 2.) fluorescent protease protection assays (Fig 2E), 3. ) selective permeabilization and immunofluorescence analysis (Fig E2D) , and 4.) in vitro translocation and protease protection (Fig E2E) . This includes quantitative data of the fluorescent protease protection assay demonstrating that the C-terminus of XBP1u is protected in the range of a luminal control protein (Fig E2C) . Of note, all previous reports on that issue did not experimentally investigate XBP1u topology (Yoshida et al., 2006; Yanagitani et al., 2009 We show by immunofluorescence microscopy that endogenous XBP1u co-localizes with an ER maker (Fig E2I), supporting Question 4. In Figure 2F , can ubiquitinated XBP1u be detected or all Ub chains removed during sample processing? In general, some demonstration of Ub conjugation would be useful to support an active role for Trc8 in this complex.
We followed on that question and provide evidence that XBP1u is polyubiquitianted (Fig E4B, E4D and E7C).
Question 5. For the mutants tested in Figure 3 , was their orientation with respect to ER membrane determined (as in Figure 2 ) and did they adopt a type II orientation with the same frequency as the wild type?
We validated type II topology of both mutants by a fluorescent protease protection assays (Fig E3A-B) .
Question 6. The 25kD fragment detected in Figure 2F is very weak and would not appear to correlate with the levels observed in Figure 4B . Can the authors comment on the relative levels of this fragment appear so different?
Experimental hurdles such as post-lysis degradation or inefficient transfer by western blotting makes detection of peptide fragments by SDS-PAGE challenging. Microscopy analysis shown in Fig 4B, however, is performed in living cells, allowing to demonstrate the real extend of peptide release.
Question 7. In Figure 5B , no difference in the amount XBP1u co-IP with SPP WT or DA is observed. If XBP1u is unable to be processed by SPP-DA, I would have expected that more might be observed. Can the authors shed some light on why no change was observed?
We acted on that concern and now show a quantification of XBP1u co-purified with SPP wt and SPP D265A (Fig E6B), revealing slight differences in the trapping efficiency. Despite that, we comment on the unexpected observation that "also SPP wt co-purified XBP1u although with a slightly reduced efficiency (Fig 6B)". Of note, a recent enzymological characterization of the E. coli rhomboid intramembrane proteases GlpG has revealed a surprising low catalytic rate (Dickey et al., 2013). Hence, we discuss (on page 16) that our result suggests "that the SPP-reaction cycle is slow", which likely is a multi-step reaction with potentially other rate limiting steps than proteolysis, given that in the 500-kDa SPP complex different factors act on the substrate.
Question 8. In Figure 7A and 7B, several prominent bands listed as "unidentifiable coimmunoprecipitated proteins" are listed. There is a striking difference between XBP1u and XBP1uΔ with respect to these bands. For instance, the higher band observed in SPP-D286A is missing as is the lowest band of DerlinG189V. It would appear that these bands represent interesting interactors or modified XBP1u forms. Could the authors address what they might represent or perhaps determine at least whether they represent XBP1u (modified) or a completely different protein.
This observation is well taken, but unfortunately analysis of these factors is not straightforward, and since we think this is not central to the manuscript we will not follow on that point.
As discussed in the response to reviewer #1 (point 5), we performed domain swap experiments with the type II membrane protein invariant chain (Fig. 8A-C and E8A-B). Interestingly, these new pulsechase experiments show that the C-terminal tail of XBP1u alone is sufficient to target a type II membrane protein to the SPP-dependent ERAD pathway.
We show by BN-PAGE analysis of immunoisolated SPP that Derlin1
G180V assembles in the 500 kDa complex (Fig E7A) .
Similarly, we used BN-PAGE to resolve this issue and favor a model where Derlin1 is part of the 500-kDA complex prior to XBP1u binding (Fig E7F).
MINOR COMMENTS Comment 1. The resolution of images in Figure E2G makes interpretation a bit difficult. Fig  E2I, previous Fig E2G) , we carefully restrict our claims and just indicate that "immunofluorescence analysis of fixed Hek293T cells showed an accumulation of endogenous XBP1u in the ER upon SPP inhibition (Fig 2H and E2I) , whereas upon epoxomicin treatment we observed accumulation of a fuzzy XBP1u signal adjacent to the ER (Fig E2I) ". Comment 2. Pg. 14, first sentence. Fig 2D should We revised the manuscript accordingly.
Since indirect immunofluorescence analysis of fixed cells does not allow a higher resolution (
Referee #3:
This reviewer brings up critical points that we discuss in the following.
Contrary to the current consensus in the field that XBP1u is a peripheral membrane protein in the ER (located entirely on the cytosolic side), the authors claim that XBP1u is synthesized as a type II transmembrane protein in the ER and degraded by a 500-kDa ERAD complex consisting of SPP, Derlin-1 and TRC8. However, if intramembrane cleavage of XBP1u by SPP triggers subsequent proteosomal degradation, the authors must observe both full length XBP1u and cleaved form of XBP1u in pulse chase experiments. This reviewer cannot believe the authors' story until the authors provide convincing data for the two-step cleavage of XBP1u (first by SPP and second by proteasome) by pulse chase experiments. N-terminal fragment of XBP1u observed was too faint in cycloheximde chase experiment (Fig. 2F) to support the authors' claim.
The referee is right that upon inhibition of the proteasome, we do not see full conversion of XBP1u to soluble cleavage fragments (an observation that we point out on page 11 and 14). Similarly, for most substrates of classical dislocation pathways, proteasome inhibitor treatment leads to substrate accumulation in the ER membrane fraction (and only to partial dislocation into the cytosol). Because of this feedback inhibition between the proteasome and the SPP-dependent ERAD machinery, we cannot work out a substrate product relationship.
The referee is right that it would be nice to understand how inhibiting the proteasome interplays with earlier steps, also blocking ERAD on the level of the ER membrane. However, given the extreme experimental challenges deciphering this problem, this analysis is beyond the scope of this manuscript.
Identification of the 500-kDa SPP-Derlin1-TRC8 complex was interesting to this reviewer, however, the XBP1u part probably represents an artifact resulting from overexpression of XBP1u, because there are a lot of discrepancy in the data. Discrepancy 1) a) Immunofluorescence; XBP1u-N-GFP is localized only in the ER in Fig. 2B . However, bright fluorescence from XBP1u-N-GFP and XBP1u-C-GFP was seen in the nucleus (Fig. 2E and Fig.  E2A and E2B) .
We have revisited the original data and selected a more representative picture that also shows XBP1-N-GFP in the nucleus, although at a very low level (Fig 2B) . Hence we have changed our wording, now stating (on page 8) that "GFP-tagged XBP1u co-localized with the ER maker RFP-KDEL and only weak cytosolic or nuclear signals were detected". Fig. 2F ; XBP1u exists as full-length (ER) form in epoxomicin-treated cells, whereas bright fluorescence was observed in the nucleus of epoxomicin-treated cells expressing XBP1u-GFP in Fig. 4B . (Fig 2F) and fluorescence microscopy analysis under steady state conditions (Fig 4B) reveal these two populations to a different extend.
1) b)
As discussed above, inhibition of the proteasome leads, besides of accumulation of the SPP-released N-terminal fragment, also to stabilization of the full-length XBP1u. Due to experimental differences, western analysis of a cycloheximide chase experiment
We explicitly indicate this discrepancy. In the results section we now conclude that our results in living cells more clearly show that degradation of XBP1u is triggered by SPP-catalyzed release that is followed by proteasomal degradation of the N-terminal fragment.
1) c) Only half of XBP1u remained associated with ER membrane after sodium carbonate wash in Fig. 2C . Only small fraction of FLAG-XBP1u was glycosylated (Fig. 2D) . (Rainer, Chem. Rev. 1998) . Despite that, we did not intend to exclude that XBP1u has also other fates, and hence indicate (on page 9) "that a fraction of XBP1u may be peripheral attached as stalled nascent chains and translocation intermediates, as has been suggested (Yanagitani et al., 2009) ."
This is not a discrepancy. Sodium carbonate extraction depends on the properties of the
Despite these facts, degradation of XBP1u was blocked almost completely by co-expression with SPP mutant D265A in Fig. 5A , which seems too effective than expected to this reviewer. The authors must show how much of XBP1u stays in the ER as a type II transmembrane protein quantitatively.
We show by immunofluoresnce microscopy of SPP D265A expressing cells that XBP1u remains a type II membrane protein (Fig E6A) .
2) Fig. 6 ; why did cleavage-deficient XBP1u mutant mt2 reduce expression of UPR reporter? If the authors' claim is correct, XBP1u mutant mt2 remains associated with the ER, and therefore is unable to down regulate XBP1s. The data in Fig. E4 Fig. 2G ; show the band of XBP1s in western and show the bands of cDNA corresponding to XBP1s and XBP1u mRNA by RT-PCR to say that epoxomicin treatment reduced XBP1u levels probably by IRE1-mediated reduction of the XBP1 pre-mRNA, which upon accumulation of unfolded proteins activates the canonical UPR signaling. (Fig E2G) . Fig. 3A; show the localization and topology of the two mutants and examine whether the two mutants are cleaved or not cleaved by SPP as in Fig. 4C .
We show by an RT-PCR assay that under these conditions UPR is induced
2)
We validated the type II topology of both mutants by a fluorescent protease protection assays (Fig  E3A-B) . Since both mutants are not degraded the SPP-dependent ERAD pathway (Fig 3A) , we conclude that they are not cleaved. Thank you for submitting your revised manuscript for our consideration. It has now been reviewed once more by two of the original referees, whose comments are copied below. While both reviewers consider the paper generally improved and most points satisfactorily addressed, they still have a couple of specific points that would require further modification of the manuscript -in particular the major concern of referee 1 and the related point 4 of referee 2. Since I agree with referee 1 that these issues potentially affect the main conclusions of the study, I am thus returning the study to you for one additional, final round of revision, in order to clarify these points.
I hope you will be able to make the necessary further minor revisions (which I consider justified given the importance of the topic and the potential significance of the conclusions) and resubmit a final version of the manuscript (together with a response letter) as early as possible. Should you have any further questions in this regard, please do not hesitate to get back to me.
Chen and colleagues have significantly improved their manuscript and adequately addressed most of my previous points. However, I am still puzzled about the extent by which XBP1u cleavage occurs by SPP. Is cleavage by SPP only a minor fraction of total XBP1u cleavage (in which case the whole story would be of less general interest)? Or does SPP mediate a large fraction of total XBP1u cleavage, making it a finding of wider interest. Fig 2G suggests that the SPP inhibitors strongly stabilize the endogenous XBP1u, which would argue for a more central role of SPP in XBP1u cleavage. In contrast the newly added Figure E4D suggests that a stabilization (inhibition of cleavage) of this tagged XBP1u only occurs with epoxomycin (proteasome inhibitor), but not with the SPP inhibitors, suggesting predominant proteasome cleavage.
The authors should address this point.
Referee #2:
SUMMARY
In this revised manuscript, the authors explore a putative role for the intramembrane protease signal peptide peptidase (SPP) in ER-associated degradation (ERAD). In doing so, they identify and characterize and interactions of SPP with Derlin1, an established ERAD component and putative rhomboid-like protease, and Trc8, an ER-resident ubiquitin ligase implicated in previously in US2-induced degradation of MHC Class I. They describe a regulatory protein of the Unfolded Protein Response (UPR), XBP1u (unspliced) as a substrate of SPP. They now include data using 4 different methods to demonstrate that XBP1u adopts a type II orientation by virtue of a previously uncharacterised transmembrane domain. The authors present data that Derlin1 acts in the context of a receptor for XBP1u in order for SPP to access it. XBP1u does not seem to lose its ectodomain due to an interaction with Derlin1. The authors also provide evidence that the XBP1u form attenuates XBP1s action (and hence UPR activation) by targeting it for degradation. Collectively, the authors have proposed an SPP regulated mechanism of UPR tuning through degradation of XBP1s via XBP1u.
The findings presented by Chen et al. reveal several novel aspects regarding the relationship between ERAD and UPR regulation. They demonstrate the presence of Derlin1 in a 500kD complex with SPP and Trc8 that also binds XBP1u. They now provide even more data to convincingly show that XBP1u can adopt the conformation of a type II membrane protein, for which the hydrophobic sequence responsible is cleaved by SPP. A role for Derlin1-mediated recognition of the XBP1u ectodomain is also clearly demonstrated. Overall the revised manuscript is well written, with the additional data welcomed and effectively integrated. Overall, this work has been significantly improved and represents an important set of observations in the field of ER stress regulation.
RESPONSE TO REBUTTAL
Overall, the authors have basically addressed most of the points this reviewer has raised during the first round of evaluation.
1. In response to the question of Derlin1-SPP interaction discrepancy with other published work, the authors have satisfactorily explained their differences.
2. In response to concerns of the XBP1u putative topology, the authors have now convincingly demonstrated the topology of XBP1u using four independent assays.
3. In response to the query of endogenous XBP1u orientation, the lack of available reagents is unfortunate but understandable and the absence of any conclusion on this point does not adversely affect the conclusions drawn from this study.
4. With respect to ubiquitination of XBP1u, the authors have made some effort to demonstrate this point, however the banding patterns of the Ub western blots (particularly E4B) are not overly convincing. I would recommend that if an additional sample of XBP1u IP treated with epoxymycin was treated with a recombinant deubiquitinating enzyme (e.g. Usp2cc) and resulted in a disappearance of the HMW bands, it would go a long way to making this point more convincing.
5. The authors have now included fluorescence protease protection assays on the XPP1u mutants to confirm their orientation.
6. Regarding the apparent inconsistency of XPB1u fragment levels, the argument for limiting amounts due to post-lysis degradation could make detection difficult I suppose.
7. In response to the issue of lack of difference in XBP1u co-IP with SPP-WT and -DA, the authors have now included a quantification demonstrating a slightly increased level of interaction with the dominant-negative SPP, as would be expected. The added discussion regarding enzymatic processing rates of SPP is also welcomed.
8. With respect to the unidentifiable bands in Figure 7A & B, the argument that they are beyond the scope of this manuscript is satisfactory.
9. To address the concern of ectodomain specificity, the authors inclusion of additional date using chimeras with CD74 helped to clarify this point and helped to demonstrate the sufficiency of the XBP1u C-terminal tail.
10. To address the concern of assembly of the Derlin1-G170V mutant, the BN-PAGE included is sufficient.
11. The query into the presence of Derlin1 in the SPP-Trc8 complex with the XPB1u mutant, the BN-PAGE figure in E7F clearly demonstrate its presence, even though the temporal aspects are not resolved.
MINOR COMMENTS
Most of the comments from the original review have been satisfactorily addressed. However, on pg. (Weihofen et al., 2003 JBC; Bland et al. 2003, JBC) . Over all we provide several lines of evidence that the predominant pool of XBP1u is degraded by the concerted action of SPP and the proteasome.
4. With respect to ubiquitination of XBP1u, the authors have made some effort to demonstrate this point, however the banding patterns of the Ub western blots (particularly E4B) are not overly convincing. I would recommend that if an additional sample of XBP1u IP treated with epoxymycin was treated with a recombinant deubiquitinating enzyme (e.g. Usp2cc) and resulted in a disappearance of the HMW bands, it would go a long way to making this point more convincing. (Christianson et al., 2011; Lee et al., 2010; Stagg et al., 2009 )…".
